Clinical Trial Update: A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2 [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports NPX887 for solid tumors expressing B7-H7/HHLA2. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Neoplasm

Drugs mentioned

• NPX887

Snippet

Sponsor: NextPoint Therapeutics, Inc. | Conditions: Metastatic Malignant Neoplasm | Phase 1 | Status: RECRUITING